Filtered By:
Source: Vaccine
Vaccination: Covid Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 44 results found since Jan 2013.
The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers
CONCLUSIONS: The prevalence of SIRVA is estimated at 3% in the adult working population. Signs and symptoms of SIRVA are variable in severity, localization and timing. Soft-tissue abnormalities is the most common clinical sign. This study contributes to clinician's knowledge on SIRVA, aiding in early recognition and treatment, which are imperative for prevention of persistent and severe shoulder pathology.PMID:37635003 | DOI:10.1016/j.vaccine.2023.08.043
Source: Vaccine - August 27, 2023 Category: Allergy & Immunology Authors: Esther R C Janssen Astrid Z van Montfoort Freek Hollman Frederik O Lambers Heerspink Source Type: research
Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population
CONCLUSIONS: Some adverse reactions to the COVID-19 vaccination are a greater risk of symptoms in the younger group, women, and participants with lower BMI. Care should be taken to monitor women, younger people, and individuals with a low body mass index for adverse effects after receiving the COVID-19 vaccination.PMID:37455163 | DOI:10.1016/j.vaccine.2023.04.053
Source: Vaccine - July 16, 2023 Category: Allergy & Immunology Authors: Xi Lu Shota Masuda Hasita Horlad Takahiko Katoh Source Type: research
Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination
CONCLUSION: Menstrual disturbances were common regardless of vaccination. We found increased risk of menstrual disturbances after vaccination, particularly for heavier bleeding than usual, prolonged bleeding, shorter interval between menstruations, and stronger period pain. In the future, menstrual characteristics should be included in vaccine trials.PMID:37451876 | DOI:10.1016/j.vaccine.2023.06.088
Source: Vaccine - July 14, 2023 Category: Allergy & Immunology Authors: Lill Trogstad Ida Laake Anna H Robertson Siri Mjaaland Ida H Caspersen Lene K Juvet Per Magnus Kristine Blix Berit Feiring Source Type: research
Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens
CONCLUSION: The frequency of immediate adverse reactions was highest among females and younger persons, however, most of the Danish citizens did not experience immediate adverse reactions following COVID-19 vaccination.PMID:37391313 | PMC:PMC10288319 | DOI:10.1016/j.vaccine.2023.06.069
Source: Vaccine - June 30, 2023 Category: Allergy & Immunology Authors: K Torp Hansen F Kusk Povlsen B Hammer Bech S Nygaard Hansen C Ulrikka Rask P Fink T J ørgensen H Nielsen T Meinertz Dantoft S Marie Thysen D Rytter Source Type: research
Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022
CONCLUSION: Our review confirmed previously established safety risks for TTS and GBS and identified a potential safety concern for myocarditis.PMID:37321898 | PMC:PMC10264169 | DOI:10.1016/j.vaccine.2023.06.023
Source: Vaccine - June 15, 2023 Category: Allergy & Immunology Authors: Emily Jane Woo Julianne Gee Paige Marquez James Baggs Winston E Abara Michael M McNeil Rositsa B Dimova John R Su Source Type: research
Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University
CONCLUSION: This study demonstrated that a heterologous second booster dose of BNT162b2 after two doses of CoronaVac induced elevated IgG against the SARS-CoV-2-spike protein and caused minor adverse reactions in healthcare workers of the Faculty of Medicine, Naresuan University. This study was registered as Thailand Clinical Trials No. TCTR20221112001.PMID:37301707 | PMC:PMC10239901 | DOI:10.1016/j.vaccine.2023.06.017
Source: Vaccine - June 10, 2023 Category: Allergy & Immunology Authors: Supawadee Makanut Apirath Wangteeraprasert Wittawat Jitpewngam Jatuporn Ngoenkam Sutatip Pongcharoen Source Type: research
COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study
In conclusion, COVID-19 vaccination was associated with a ∼1 day temporary increase in menstrual cycle length, but was not appreciably associated with other menstrual cycle characteristics.PMID:37301706 | PMC:PMC10239900 | DOI:10.1016/j.vaccine.2023.06.012
Source: Vaccine - June 10, 2023 Category: Allergy & Immunology Authors: Amelia K Wesselink Sharonda M Lovett Janice Weinberg Ruth J Geller Tanran R Wang Annette K Regan Mary D Willis Rebecca B Perkins Jennifer J Yland Martha R Koenig Kenneth J Rothman Elizabeth E Hatch Lauren A Wise Source Type: research
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old
CONCLUSIONS: Safety and immunogenicity of coadministered PCV20 and BNT162b2 were similar to those of PCV20 or BNT162b2 administered alone, suggesting that the 2 vaccines may be coadministered.TRIAL REGISTRATION: ClinicalTrials.gov, NCT04887948.PMID:37244809 | PMC:PMC10165018 | DOI:10.1016/j.vaccine.2023.05.002
Source: Vaccine - May 27, 2023 Category: Allergy & Immunology Authors: David Fitz-Patrick Mariano Young Kari Yacisin Kathleen McElwee Todd Belanger Kelly Belanger Yahong Peng Dung-Yang Lee William C Gruber Daniel A Scott Wendy Watson Source Type: research
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
CONCLUSION: Even if some rare adverse events were identified, our survey of post-marketing surveillance has provided further evidence of the favourable safety profile of mRNA vaccines.PMID:37024412 | DOI:10.1016/j.vaccine.2023.03.054
Source: Vaccine - April 6, 2023 Category: Allergy & Immunology Authors: Greta Santi Laurini Nicola Montanaro Massimiliano Broccoli Giulia Bonaldo Domenico Motola Source Type: research
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan
CONCLUSION: A single dose and homologous Ad26.COV2.S booster increased antibody responses with an acceptable safety profile in Japanese adults (ClinicalTrials.gov Identifier: NCT04509947).PMID:36732164 | PMC:PMC9812825 | DOI:10.1016/j.vaccine.2023.01.006
Source: Vaccine - February 2, 2023 Category: Allergy & Immunology Authors: Yumi Tsuchiya Hiroshi Tamura Koji Fujii Hirotaka Numaguchi Kiichiro Toyoizumi Tina Liu Mathieu Le Gars Vicky C árdenas Takashi Eto Source Type: research
